The Munich-area biotech making a deliberate, almost stubborn argument: cancer resistance to immunotherapy isn't a mystery. It's a cytokine. And cytokines have antibodies.
It's a Tuesday morning at 19 Am Klopferspitz, a quiet road on the southern edge of Munich. The building is unremarkable. The science inside is not. Inside CatalYm's headquarters, a small team is checking the latest data readout from a global Phase 2b trial that, if it works, will rewire how clinicians think about checkpoint inhibitors.
CatalYm is a clinical-stage biotech with one molecule, one target, and one very specific argument: when immunotherapy fails - and it fails for most patients - the reason is often a single tumor-derived protein called GDF-15. Neutralize it, and the immune system can see the tumor again.
That, at least, is the bet. It is also now backed by a $150M Series D, a paper in Nature, and a series of clinical signals that biotech investors have been waiting almost a decade to see.
In the 2010s, anti-PD-1 antibodies rewrote the oncology textbook. Melanoma patients who would have died in months were, suddenly, not dying. The Nobel Prize followed. So did the headlines.
But the headlines mostly skipped the part where, for the majority of solid tumor patients, checkpoint inhibitors did very little. Or worked, then stopped working. Or worked for a while in some lucky responders and never showed up at all for the rest. Oncologists, being polite, called this resistance. Patients called it something less polite.
The cause, it turned out, wasn't a single thing. The tumor microenvironment is a small city of immune-suppressing signals, and pharmaceutical companies have been trying to name them one by one. Some bets - on TGF-β, on IDO - did not pay off as hoped. CatalYm picked a different name from the list: GDF-15.
CatalYm was spun out in 2016 from the Julius-Maximilians-Universität Würzburg, on the back of research by Prof. Dr. Joerg Wischhusen. His lab had spent years on a protein the rest of the field largely ignored. GDF-15 was known mainly because pregnant women have a lot of it. Tumors, it turned out, also have a lot of it. And tumors with the most of it were the ones least likely to respond to immune therapy.
If that sounds like the kind of correlation a biotech could be built on - that's because it was. Co-founders Manfred Ruediger, Eugen Leo and Christine Schuberth-Wagner turned the academic insight into a company. By 2021, industry veteran Dr. Phil L'Huillier was steering it through clinical development. The CEO chair is now held by Scott Clarke, a former Tizona Therapeutics and Roche oncology executive based on the US side of the operation.
The bet is small in scope and large in implication: one antibody, one target, against one of the most stubborn problems in modern oncology.
Visugromab - the generic name for CTL-002 - is a humanized monoclonal antibody. It binds GDF-15 and removes its immunosuppressive effect inside the tumor microenvironment. The mechanism, on paper, is almost suspiciously elegant: when GDF-15 is neutralized, immune cells can again infiltrate the tumor, activate, proliferate, and signal interferon-γ. The tumor that had been hiding gets seen.
Crucially, visugromab is being developed in combination with anti-PD-1 therapy, not as a replacement. It is, in the language of the trade, a resistance reversal agent. If the working metaphor for checkpoint inhibitors is "release the brakes on the immune system," visugromab's pitch is closer to "remove the speed bump the tumor put down."
And there is a second story attached. GDF-15 also drives cachexia, the wasting syndrome that quietly kills many late-stage cancer patients. Neutralize the protein in the tumor microenvironment and you may, at the same time, address one of oncology's least-glamorous and most-fatal symptoms. Two problems, one antibody.
Biotech is a game where, for years, you have nothing - and then, briefly, you have everything. 2024 was CatalYm's "everything" year. Phase 1/2a results in Nature. Positive Phase 2a follow-up at ASCO across non-small-cell lung cancer, urothelial carcinoma and hepatocellular carcinoma. A $150M Series D round to take it forward.
CatalYm's mission statement is one sentence long, and it is not particularly poetic. "Pioneers in neutralizing GDF-15 to overcome cancer therapy resistance." That is the entire pitch. A more rhetorical company would have layered metaphors on top of it. CatalYm did not, and the restraint is worth noticing.
This is what a focused biotech looks like in 2026: one target, one molecule, one combinable mechanism, and a series of trials designed to answer one question - does removing this cytokine, in this kind of patient, in combination with the standard of care, materially improve outcomes?
The Bayern biotech corridor, which incubated MorphoSys and Medigene before this, has produced its share of focused single-asset companies. Some made it. Some did not. CatalYm has, at minimum, earned the right to be in the conversation.
Here is the implication, if visugromab continues to read out the way Phase 1/2a suggested. Tumors currently labeled "checkpoint-resistant" - which is most of them, in most indications - become potentially treatable with the same checkpoint inhibitors that already exist, just with an antibody added on. Patients with cachexia, who currently have almost no options, may gain one. And GDF-15, an obscure cytokine that for years lived mostly in the pregnancy literature, becomes a target with a class around it.
None of this is guaranteed. Phase 2b trials have a way of being humbling. But the structural argument - that resistance is not noise, that it has a name and a binding site - is now testable in a way it wasn't five years ago.
Back at 19 Am Klopferspitz, on a Tuesday morning, a small team continues to check the data. The building is still unremarkable. The molecule is still one molecule. The thesis is still one thesis. And the patients - non-responders to anti-PD-1, slowly losing weight, slowly running out of options - are still the reason any of this exists.
If the bet works, the morning meeting becomes one of those small rooms where, in retrospect, a piece of oncology was quietly rewritten. If it doesn't, it becomes a careful, well-funded test of an idea that needed testing. Either way, the work is the same. Tomorrow, the team checks the data again.